bristol-my squibb announc would acquir celgen celg
cash stock bm celgen creat innov
biopharma leader lead franchis deep broad pipelin
drive sustain growth deliv new option patient across rang
seriou diseas
agreement celgen sharehold receiv one bristol-my
squibb share cash celgen share held per share
premium celgen wednesday close share bristol slid
share celgen surg shortli announc
deal good celgen struggl endur
past year stock hit high per share back septemb
steadili trade lower ever sinc deal get sharehold
back stock price high achiev back least lift stock
better valuat compar beforehand
strong move bm need bounc back major
competitor merck bristol-my start top player cancer
immunotherapi opdivo howev merck keytruda perform
much better front-lin lung cancer space acquisit allow
bristol-my test lot combin previous
possibl front-lin lung cancer cancer indic
huge deal pharma sector good bristol-my
ad cancer product pipelin sharehold celgen
well bristol-my squibb strateg prioriti approach busi
develop met transact
howev acquisit add new debt bristol-my order
complet acquisit take account celgen debt
deal come skeptic whether price tag worth risk
bristol-my squibb celgen corpor announc januari
enter definit merger agreement bristol-
myer squibb acquir celgen cash stock transact equiti
valu
term agreement celgen sharehold receiv bristol-
myer squibb share cash share celgen celgen
sharehold also receiv one tradeabl conting valu right cvr
share celgen entitl holder receiv payment
achiev futur regulatori mileston board director
compani approv combin
bristol-my squibb global biopharmaceut compani whose mission
discov develop deliv innov medicin help patient prevail
seriou diseas
celgen corpor headquart summit new jersey integr
global biopharmaceut compani engag discoveri develop
commerci innov therapi treatment cancer
inflammatori diseas next-gener solut protein
homeostasi immuno-oncolog epigenet immunolog neuro-
complementari area focu combin compani oper
global reach scale maintain speed agil core
transact creat lead focus specialti biopharma compani well
posit address need patient cancer inflammatori
immunolog diseas cardiovascular diseas high-valu innov
medicin lead scientif capabl
term financ
base close price bristol-my squibb stock januari
cash stock consider receiv celgen sharehold valu
cash stock consider repres premium celgen
sharehold base volum weight averag close stock price
celgen prior sign also repres premium celgen
sharehold base close stock price celgen januari
share also receiv one tradeabl cvr entitl holder
receiv one-tim potenti payment cash upon fda approv
three ozanimod decemb liso-cel decemb
march case specifi indic
transact subject financ condit cash portion
fund combin cash hand debt financ bristol-my
squibb obtain fulli commit debt financ morgan stanley senior
fund inc mufg bank ltd follow close transact bristol-
myer squibb expect substanti debt combin compani
pari passu rate
bristol-my squibb expect execut acceler share repurchas
program subject close transact market
condit board approv
follow close transact dr caforio continu serv
chairman board chief execut offic compani
member celgen board ad board director
bristol-my squibb combin compani continu strong
approv time close
transact subject approv bristol-my squibb celgen
sharehold satisfact customari close condit regulatori
approv bristol-my squibb celgen expect complet transact
 co llc serv lead financi advisor bristol-my
squibb evercor dyal co llc serv financi advisor bristol-
myer squibb kirkland elli llp serv bristol-my squibb legal
counsel morgan secur llc serv lead financi advisor citi
act financi advisor celgen wachtel lipton rosen katz serv
legal counsel celgen
compel transact financi perspect
strong return signific immedi ep accret transact
intern rate return expect well excess celgen
bristol-my squibb cost capit combin expect
accret bristol-my squibb ep stand-alone
basi first full year follow close transact
strong balanc sheet cash flow gener enabl signific
invest innov expect free cash
flow gener first three full year post-clos compani
commit maintain strong invest grade credit rate
continu dividend polici benefit bristol-my squibb
celgen sharehold bristol-my squibb also signific
financi flexibl realiz full potenti enhanc late-
meaning synergi bristol-my squibb expect realiz run-rat
cost synergi bristol-my squibb confid
achiev effici across organ maintain strong core
commit innov deliv valu portfolio
total synergi
area opportun
celgen sharehold receiv cash one bm share one cvr bm
structur cvr align interest bristol-my squibb celgen
sharehold scenario multipl success near-
term portfolio cvr paid three product approv
appropri time view clear value-cr scenario
sharehold compani
bm project free cash flow first combin
provid flexibl deliv maintain strong investment-
bm intend execut acceler share repurchas program
transact close repurchas portion equiti issu
transact bm obtain fulli underwritten bridg facil
mufg
bm equiti issu celgen
bristol-my celgen leverag power combin asset
peopl technolog extend strengthen foundat
posit compani long-term sustain growth broaden
market portfolio augment diversifi pipelin maintain speed
agil central approach
lead franchis complementari product portfolio provid
enhanc scale balanc combin compani nine product
annual sale signific potenti growth
core diseas area oncolog immunolog inflamm
lead oncolog franchis solid tumor hematolog
malign led opdivo yervoy well revlimid pomalyst
top five immunolog inflamm franchis led orencia
cardiovascular franchis led eliqui
near-term launch opportun repres greater billion
revenu potenti combin compani six expect near-term
immunolog inflamm ozanimod
four hematolog luspatercept liso-cel
launch leverag combin commerci capabl two
compani broaden enhanc bristol-my squibb market
posit innov differenti product addit
signific number life-cycle manag registr readout expect
immuno-oncolog io
early-stag pipelin build sustain platform growth
combin compani deep divers early-stag pipelin
across solid tumor hematolog malign immunolog
inflamm cardiovascular diseas fibrot diseas leverag
combin strength innov
early-stag pipelin includ high potenti asset mani
import data readout near-term significantli enhanc
early-stag pipelin bristol-my squibb well posit long-
term growth signific valu creation
power combin discoveri capabl world-class expertis
broad rang modal
togeth compani expand innov capabl
homeostasi antibodi engin cell therapi
furthermor strong extern partnership provid access addit
bristol-my squibb strateg prioriti approach busi develop
met transact great therapeut fit across
compani oncolog immunolog inflamm pipelin
scientif capabl celgen tremend opportun
bristol-my squibb celgen two innovation-focus compani
build even stronger compani one mission discov
develop deliv innov medicin patient unmet
need across continuum care
celgen sharehold cash stock transact recogn unlock
signific valu deliv immedi substanti cash valu
provid meaning particip combin compani futur own
compani close
celgen sharehold also benefit addit cash via dividend
potenti cvr payment strateg vision transact obviou
compel significantli enhanc strong global leadership oncolog
vault inflamm immunolog busi global top tier
togeth bristol-my squibb celgen financi strength
acceler research develop engin sustain long-term
growth addit combin compani continu invest
extens portfolio research partner
balanc lead commerci portfolio
bm count lead franchis four core therapeut area larg
grow market combin portfolio willdiversifi revenu stream also
provid platform sustain leadership
balanc lead commerci portfolio
strong io busi meaning growth opportun
i/o portfolio key pillar treatment solid tumor bm driven
strong commerci execut i/o annual sale
approv opdivo indic four year follow
launch i/o busi continu perform well highli competit
market bm strong commerci momentum lead share core
bm continu strong lead i/o busi futur
ensur commerci team remain focus deliv
valu busi
advanc scienc io
near-term product launch opportun potenti greater
revenu
luspatercept regulatori submiss expect
md beta-thalassemia
liso-cel car-t strong efficaci potenti differenti safeti
toler profil r/r dlbcl
potenti first- possibl best-in-class bcma car-t multipl
fedratinib target patient relaps intoler jakafi
ozanimod nda eu submiss rm plan
biologic-lik efficaci psoriasi upsid potenti address multipl
key valu driver transact fact combin compani
six potenti product launch next month
signific revenu potenti two potenti launch
immunolog inflamm ozanimod four launch
launch leverag combin commerci capabl across oncolog
immunolog inflamm broaden bristol-my squibb market
posit innov differenti product asset
potenti gener greater peak sale ad scale
breadth immunolog oncolog franchis well first
step next stage hematolog leadership
deep broad combin pipelin
high potenti agent pipelin asset watch
strong volum growth across brand
recommend buy rate celg maintain tp
estim tp base forward
price-to-earnings multipl estim adjust ep
provid upsid potenti
tp unchang recommend chang
buy rate due increas upsid potenti upsid
potenti increas due fall stock price
septemb base previou report
perform line estim
estim base follow factor strong top-
line bottom-lin perform quarter growth
volum across brand acquisit juno impact
advanc late-stag pipelin
celgen deliv strong top-lin bottom-lin perform
due growth volum across brand revlimid
pomalyst/imnovid otezla abraxan
total product net sale grew y/i
growth due volum increas price
contribut slightli off-set neg impact
celgen report net incom ep
adjust net incom increas
adjust ep increas
compani namecelgen corporationtickercelgstock ratingbuyupgradeindustri viewoverweightpositivepric week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth bristol-my celgene| januari
inflamm immunolog franchis
excel result y/i otezla sale growth
strong momentum due world-wide volum
increas continu expand access pre-biolog
hematolog oncolog franchis robust
result revenu y/i growth
revlimid pomalyst/imnovid continu drive
overal growth volum gain across brand
celgen acceler in-line late-stag product
earli pipelin posit ph trial across
portfolio ytd advanc late-stag asset ozanimod
fedratinib luspatercept liso-cel expect
launch
celgen made signific progress regulatori
file ozanimod europ track
submit applic
current price-to-earnings
due fall stock price price-to-earnings trail
averag price-to-earnings till
expect forward price-to-earnings
celgen expect revenu
expect ep rang
recommend buy rate celg base
perform period expect
top-lin revenu grow
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior month error dividend split forward annual dividend rate n/a forward annual dividend yield n/a trail annual dividend rate n/a trail annual dividend yield n/a year averag dividend yield n/a pay-out dividend date n/a ex-dividend date n/a last split factor new per last split date jun inform bristol-my celgene| januari
non reconcili refer page
incom statement item total gross research develop sell gener administr sg oper interest incom interest incom incom incom net incom outstand dilut ep dilut ep actual annual estim annual actual quarterli bristol-my celgene| januari
 market account total prepaid current total current build machineri furnitur total fix non-curr defer incom taxes- non-curr total non-curr total equiti liabilitiesaccount accru defer current liabilities- total current long-term defer incom non-curr minor interest total non-curr total prefer stock equity- common stock addit paid-in retain treasuri total total total liabil stock actual annual actual quarterli balanc sheet item bristol-my celgene| januari
net cash provid oper activ decreas period
compar decreas due acquisit impact well increas
cash paid incom tax
net cash use invest activ increas period compar
increas due payment acquisit juno net cash
net cash use financ activ increas period compar
increas due payment share repurchas program
defer incom oper increas decreas increas decreas current assets- decreas increas decreas increas current liabilities- decreas increas work non- net continu net discontinu operations- net total oper invest activitiessal properti plant equipment- purchas properti plant equipment- acquisitions- net invest financ activitiesissu issuanc capit stock- repurchas capit payment dividends- financ charg net- discontinu financ activities- net financ net floweffect exchang rate net chang begin end bristol-my celgene| januari
celgen strong top-lin bottom-lin momentum quarter net
sale increas net incom increas quarter
total revenu increas compar
reflect increas unit state
net product sale increas compar
increas compris net volum increas
net price increas increas volum due
increas unit sale revlimid pomalyst /imnovid otezla
price impact attribut net price increas
partial off-set net price decreas across intern market
cog increas compar
cog sale increas compar
due raw materi charg record
 expens decreas compar
 total revenu increas
compar decreas relat reduct
expens relat collabor agreement decreas
partial off-set increment expens relat
acquisit juno includ share-bas compens expens
adjust expens increas compar
sg expens increas compar
sg total revenu increas
compar adjust sg expens
compar increas due
increment expens due acquisit juno includ
share-bas compens expens well increas
market relat expens
compar
reflect increas
unit
state
increas
compar
amort acquir
increas
compar
increas
compar
amort acquir intang asset increas
compar effect celgen
reduc remain estim use life abraxan intang asset
result recent settlement patent-rel proceed result
acceler amort amort expens also increas
result technolog platform asset acquir acquisit juno
acquisit relat charg restructur net net charg
compar net charg net charg
relat increas fair valu liabil relat publicli trade
conting valu right cvr issu part
acquisit abraxi bioscienc inc net charg also includ charg
relat current period net chang fair valu juno
interest invest incom net decreas compar
due lower invest balanc compar
interest expens increas compar
increas due interest expens associ
issuanc senior note well issuanc
senior note februari
effect tax rate compar
increas effect tax rate due decreas excess tax benefit
employe stock compens deduct decreas tax benefit
non-recur chang estim relat research
develop orphan drug tax credit
net incom increas compar
adjust net incom increas
compar ep increas
compar non-gaap ep increas
compar
oper cash flow compar
celgen receiv share upon final settlement
acceler share repurchas asr program commenc
total number share repurchas asr agreement
weight averag price per share celgen end quarter
cash cash equival market debt secur publicly-trad
period total revenu increas
compar reflect increas unit
state intern market
total net product sale period increas
compar increas compris net
volum increas net price increas increas
volum due increas unit sale revlimid otezla pomalyst
/imnovid price impact attribut net price increas
off-set price decreas across intern market
period cog increas
compar cog revenu
month period compar
period expens increas
compar total revenu
period compar increas due
higher research develop asset acquisit expens relat
purchas impact biomedicin inc impact compar
two acquisit increment expens
relat acquisit juno includ share-bas
compens expens also contribut increas
compar
reflect
increas
unit state
intern
compar
compar
month period
compar
ep
period
compar
period sg expens increas
compar sg expens total revenu
foe period compar increas
due increment expens relat acquisit juno
includ share-bas compens expens increas also
due increas market relat expens increas
donat independ non-profit patient assist organ
amort acquir intang asset
period compar effect celgen
reduc remain estim use life abraxan intang asset
result recent settlement patent-rel proceed result
acceler amort amort expens also increas
result technolog platform asset acquir acquisit juno
acquisit relat charg restructur
period compar net charg relat
acquisit restructur cost associ acquisit
juno addit net charg also includ charg relat
current period net chang fair valu juno
interest invest incom net decreas period
compar due lower invest balanc
compar prior year period
interest expens increas compar
due interest expens associ issuanc
senior note well issuanc senior note
februari
period effect tax rate compar
net incom declin period
compar ep period
compar
/imnovid otezla abraxan vidaza azacitidin inject gener
version vidaza thalomid sold thalomid thalidomid celgen
outsid idhifa addit earn revenu
product sale licens arrang
total product sale
 increas
compar
total product sale increas compar
total product sale increas
month period compar revenu
decreas compar
revenu declin compar
total product sale increas
compar total product sale increas
period compar
total intern product sale increas
compar total intern sale
period increas compar
total revenu revlimid increas
compar period total revenu
increas compar
total revenu increas compar
period total revenu
increas compar
total intern revenu increas
compar period total
intern revenu increas compar
total revenu
revlimid increas
compar
sale growth volume-driven due global increas treatment durat
market share sale growth increas due price
unit sale increas volum growth partial off-set net
total revenu pomalyst /imnovid increas
compar period
total revenu increas compar
total revenu increas
compar period total revenu
 increas compar
total intern revenu increas
compar period total
intern revenu increas compar
increas due increas sale market sale
growth increas due unit sale price increas increas
market share treatment durat contribut increas unit
sale addit intern unit sale increas due increas
treatment durat europ japan volum growth
partial off-set net price decreas
total revenu otezla increas
compar period total revenu
increas compar
total revenu
increas
compar
total revenu
otezla increas
compar
total revenu increas
compar period total revenu
 increas compar
total intern revenu increas
compar period total intern
revenu increas compar
 sale growth increas due unit sale increas result
manag care contract execut contribut
higher gross-to-net charg volum increas intern market led
japan launch
total revenu abraxan increas
compar period total revenu
increas compar
total revenu increas
compar period total revenu
 increas compar
total intern revenu increas
compar period total
intern revenu increas compar
increas due increas global unit sale sale growth
increas due unit sale price increas volum
growth partial off-set net price decreas
 increas
compar
total revenu
compar
product sale includ idhifa vidaza gener azacitidin
inject thalomid istodax
total product revenu decreas
compar period total revenu
decreas compar
sale decreas due decreas vidaza net sale partial off-set
increas idhifa net sale launch
total product
revenu decreas
compar
total revenu decreas
compar period total revenu
 increas compar
total revenu decreas
compar period total
intern revenu decreas compar
inflamm immunolog franchis result
robust world-wide growth otezla
growth y/i
 contract strategi continu contribut top-line result
solid ex-u perform driven share gain key market
growth y/i
enhanc otezla profil
posit ph data styletm scalp psoriasi
submit behet diseas snda
build diversifi portfolio asset
ozanimod rm regulatori file eu track
posit ph ii data hero trial evalu eoe
advanc develop early- mid-stag pipelin asset
strong net product sale oper momentum
net product sale increas y/i
sale perform driven strong demand across geographi
revlimid continu grow across geographi nsct post-
pomalyst/imnovid growth continu gain market share
durat
posit phase augment data rr indol lymphoma
expect
posit phase data abraxane/io combin regimen nsclc
tnbc esmo
revlimid continu
nsct post-asct
advanc expans innov pipelin
signific data pipelin expect
ph data luspatercept medalist believ
data cart liso-cel cll rrmm
rrmm
clinic program earlier line advanc
fedratinib regulatori submiss track end
american societi hematolog annual meet
collabor partner data phase
medalist believ trial luspatercept patient low-to-
intermedi risk myelodysplast syndrom md transfusion-
data phase transcend trial evalu liso-cel
patient relaps and/or refractori chronic lymphocyt
collabor partner bluebird bio data phase trial
evalu patient relaps and/or refractori multipl
data phase i/ii evolv trial evalu patient
data phase augment trial evalu revlimid
combin rituximab patient relaps and/or refractori
collabor
pharma data
phase medalist
believ trial
luspatercept patient
low-to-intermedi
syndrom md
respect
present annual
meet decemb
phase command front-lin trial evalu luspatercept
erythropoiesis-stimul agent esa -nave low low intermedi
risk md patient initi third quarter
collabor partner bluebird bio clinic program evalu
earlier line multipl myeloma advanc includ phase
ii phase trial
octob celgen announc result phase ii/iii cooper group
studi ecog conduct nation cancer institut
conjunct ecog-acrin cancer research group studi
single-ag revlimid achiev statist signific improv
primari endpoint progression-fre surviv compar observ
patient smolder myeloma data ecog studi
present futur medic meet
european societi medic oncolog esmo congress
octob efficaci safeti data present first time
atezolizumab combin abraxan patient previous
untreat metastat triple-neg breast cancer addit data
present genentech-sponsor phase trial
evalu first-lin treatment tecentriq plu chemotherapi
carboplatin abraxan patient stage iv non-squam non-
octob celgen announc phase style trial evalu
otezla patient moder sever plaqu psoriasi scalp
achiev highli statist signific improv primari
endpoint scalp physician global assess scpga respons
week compar placebo
announc result
single-
primari endpoint
progression-fre
surviv compar
observ patient
smolder
octob data
phase ii hero
patient
eoe present
unit european
addit achiev primari endpoint otezla statist
signific also met secondari endpoint whole-bodi itch
numer rate scale nr week otezla versu placebo
safeti profil otezla style studi gener consist
known safeti profil otezla new safeti signal
identifi addit phase advanc trial evalu otezla
patient mild moder plaqu psoriasi track initi year-
octob data phase ii hero trial evalu
patient eosinophil esophag eoe present unit
european gastroenterolog week uegw confer data
hero trial demonstr reduct averag esophag
eosinophil count observ week patient treat
primari endpoint sustain addit week
treatment open-label extens studi
celgen appoint dr alis reicin presid global clinic develop
celgen appoint aijaz tobaccowalla senior vice presid chief
new late-stag product expect launch
 nda eu submiss plan
northtm uc trial enrol target complet
 nda submiss myelofibrosi expect
eu submiss plan
new late-stag product expect launch
medalisttm believ present
 eu regulatori submiss expect
 approv expect
highli refractori mm
karmma
complet enrol
clinic program earlier line advanc
 approv expect highli refractori mm karmma
complet enrol
 approv expect rr dlbcl
data ph cll trial present
data present
eu japan submiss
rbc-transfus independ week
data expect
esa naiv
independ week
anemia low- low-
data expect
proport subject hematolog improv
week week compar prior
data expect
regulatori submiss plan
regulatori submiss plan
relaps refractori follicular
complet respons rate
data expect present
trial achiev superior
co-primari endpoint
data expect
regulatori submiss plan
data present
relaps refractori indol
relaps refractori b-cell
data expect
aggress relaps refractori b-cell
adjuv therapi surgic resect
data expect
trial yet enrol
area curv auc number
oral ulcer baselin week
proport subject scpga score
clear almost clear least
point reduct baselin week
data present aad
moder sever
clinic remiss assess mayo
compon sub-scor week
clinic remiss assess mayo
compon sub-scor week
enrol expect complet
moder sever activ
moder sever
proport subject
cdai score week
proport subject
cdai score
week
mainten
moder sever
proport subject
cdai score week
proport subject
ses-cd score decreas
baselin week
annual relaps rate month
month
data present ectrim
data present ectrim
nda expect resubmit
nda expect resubmit
expect submit
expect submit
trial yet enrol
total revenu
expect
total revenu expect
gaap ep expect
rang
gaap ep expect rang
adjust ep expect rang
adjust tax rate expect
celgen deliv strong top-lin bottom-lin perform
quarter total revenu increas quarter
growth due increas volum across brand net incom
increas ep increas
adjust ep increas
inflamm immunolog franchis excel result
y/i otezla sale growth strong momentum due world-wide
volum increas continu expand access pre-biolog util
hematolog oncolog franchis robust result
revenu y/i growth revlimid pomalyst/imnovid
continu drive overal growth volum gain across brand
revlimid strong global sale growth y/i
 brand grew y/i treatment durat continu increas
growth also due continu uptak front-lin non-stem cell-elig
post-stem cell transplant mainten segment well continu
increas durat use revlimid-bas triplet regimen
pomalyst/imnovid net sale increas y/i pomalyst net
sale grew y/i driven continu adopt triplet regimen
pomalyst daratumumab dexamethason relaps refractori myeloma
outsid pomalyst/imnovid revenu grew y/i volum
increas spite competit new entrant includ
celgen make excel progress toward advanc five near-term
program ozanimod fedratinib luspatercept remain target
regulatori submiss start end year
celgen continu advanc prepar bla two
program liso-cel also move forward broader
top-lin bottom-lin
perform
luspatercept remain
target regulatori
end year
non- reconcili
non- reconcili
non- reconcili
revenu growth ttm basi compar
oper margin decreas ttm basi compar due increas
ep growth decreas ttm basi compar due decreas net margin
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth bristol-my celgene| januari
mrqgross mrqoper mrqnet mrqcog mrqsg mrqr sale bristol-my celgene| januari
invest flow
sale
mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre mrqfinanci mrqreturn mrqreturn asset bristol-my celgene| januari
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per share- book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out ratio- day sale day account day convers inventori cog inventori tax rate net incom net incom discontinued- net net margin prefer dividends- annual itemsquarterli item bristol-my celgene| januari
balanc item
outstand equival market debt common prefer stock- purchas properti plant sale properti plant equipment- purchas sale business- purchas sale issuanc stock- repurchas net issuanc prefer stock- net issuanc dividends- net chang capit free bristol-my celgene| januari
current price-to-earnings due fall stock price price-to-earnings trail
averag price-to-earnings till expect forward price-to-earnings
breakdown share held share held float held institut hold institut holdersholdersharesd report outvalueblackrock vanguard group inc edgewood manag orbi gray geod capit manag northern trust top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard ishar nasdaq biotechnolog vanguard institut fund-institut spdr etf etf tr- qqq tr seri advisor inner circl fund-edgewood growth vanguard growth fidel ishar bristol-my celgene| januari
developmentsrevlimid lenalidomid demonstr signific improv progression-fre surviv compar observ random studi patient smolder multipl myelomaoctob corpor announc result open-label phase ii/iii nation clinic trial network nctn studi led ecog-acrin cancer research group sponsor nation cancer institut nci part nation institut revlimid lenalidomid provid celgen clinic trial agreement nci divis cancer treatment diagnosi base preliminari result studi safeti consist known safeti profil revlimid first result new data abraxan combin atezolizumab present esmo corpor announc first result studi evalu abraxan paclitaxel protein-bound particl inject suspens albumin-bound combin atezolizumab tecentriq patient first-lin local advanc tripl neg breast cancer tnbc studi evalu abraxane/carboplatin combin atezolizumab first-lin advanc non-squam non-smal cell lung cancer result phase impass studi show investig combin abraxan plu atezolizumab significantli reduc risk diseas worsen death first-lin metastat unresect local advanc tnbc patient compar abraxan alon random patient posit subgroup popul celgen announc phase style studi otezla apremilast moder sever scalp psoriasi primari endpointoctob corpor announc result phase style studi show otezla apremilast mg twice daili achiev highli statist signific improv primari endpoint scalp physician global assess scpga respons defin scpga score clear almost clear least reduct baselin week compar placebo otezla apremilast show meaning improv clinic quality-of-lif measur psoriasi beyond captur assess skin aloneseptemb corpor announc result two post hoc sub-analys clinic trial otezla apremilast european academi dermatolog venereolog eadv congressin pari franc find suggest otezla offer meaning improv outcom import patient moder sever plaqu psoriasi may captur common measur treatment efficaci focu skin clearanc psoriasi area sever index pasi bristol-my celgene| januari
compar
roa roi roe
ttm basi respect
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit bristol-my celgene| januari
consensu view analyst trend stock
forecast celg
compar
 average
forward price-to-earnings
celg compar
celg avgfive-year growth forecast usdgrowth high day day day estim comparisoncelgindustri avg avgprice/earn yield bristol-my celgene| januari
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr next
qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep last last last dayserrorerrorerrorerrordown last dayscurr surprisescurr growth rate bristol-my celgene| januari
stock price trade flat till septemb dip octob
stock gave neg return quarter averag volum share trade
stock price show declin trend past one year dip octob
rang stock gave neg return last one year
stock show price show declin trend sinc dip octob
stock show upward trend till surg stock given neg
return past
celgen deliv strong top-lin bottom line result quarter due volum driven growth
across brand rapid adopt key market around world recommend buy rate
stock tp provid upsid potenti stock
price show declin trend quarter
bristol-my squibb global biopharmaceut compani whose mission
discov develop deliv innov medicin help patient
prevail seriou diseas
bm pharmaceut product includ chemic synthes drug
small molecul product produc biolog process call
biolog small molecul drug administ oral form pill
tablet biolog administ patient inject
baraclud hepat franchis reyataz franchis sustiva franchis
offer product rang therapeut class includ virolog
immunosci cardiovascular product sold wholesal
retail pharmaci hospit govern entiti medic profess
across world
bristol-my squibb report revenu increas
compar period year ago revenu increas
adjust foreign exchang impact
 revenu increas compar
period year ago revenu increas
quarter adjust foreign exchang impact intern revenu
increas quarter
gross margin revenu increas quarter
due inventori charg quarter last year sg expens
decreas quarter expens decreas
quarter due ifm ifm acquisit
charg
effect tax rate quarter compar
lower tax rate due non deduct ifm acquisit
charg tax reform
bm report net earn compar
bm report non-gaap net earn
compar
gaap ep compar non-
gaap ep compar
cash equival market secur net cash
posit septemb
incom statement total gross research develop sell gener administr sg oper depreciation- oper profit interest income- incom special interest incom minor incom incom net incom outstand dilut ep dilut ep dividend paid per share actual annual actual quarterli bristol-my squibb| celgene| januari
 market account total prepaid current assets- total current build machineri furnitur total fix non-curr defer incom non-curr total non-curr total equiti liabilitiesaccount accru defer current liabilities- total current long-term defer incom non-curr minor interest total non-curr total prefer stock equity- common stock addit paid-in retain treasuri total total total liabil stock actual annual actual quarterli balanc sheet item bristol-my squibb| celgene| januari
depreciation- defer incom oper increas decreas increas decreas current assets- decreas increas decreas increas current liabilities- decreas increas work non- net continu net discontinu operations- net total oper invest activitiessal properti plant equipment- purchas properti plant equipment- net invest financ activitiesissu issuanc capit stock- repurchas capit payment financ charg discontinu financ activities- net financ net floweffect exchang rate changes- net chang begin end bristol-my squibb| celgene| januari
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom discontinued- net net margin prefer dividends- annual itemsquarterli item bristol-my squibb| celgene| januari
outstand equival market debt common prefer stock- purchas properti plant sale properti plant equipment- purchas sale purchas sale issuanc repurchas stock- net issuanc prefer stock- net issuanc net chang capit free bristol-my squibb| celgene| januari
breakdown share held share held float held institut hold institut holdersholdersharesd report outvaluewellington manag compani vanguard group inc dodg cox capit world ameripris jp morgan northern trust geod capit manag top mutual fund holdersholdersharesd report outvaluevanguard specialized-health vanguard total stock market vanguard vanguard/wellington fund spdr etf dodg cox stock vanguard institut fund-institut vanguard growth fidel ishar bristol-my squibb| celgene| januari
ytd perform
stock vs
roa roi roe
ttm
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit bristol-my squibb| celgene| januari
consensu view analyst trend stock
compar
forward price-to-earnings
compar
annual usdgrowth high day day day estim avgfive-year growth forecast comparisonbmyindustri avg avgprice/earn yield bristol-my squibb| celgene| januari
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr next
qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep revisionsn/an/an/an/aup last last daysn/an/an/an/adown last dayserrorerrorerrorerrordown last dayscurr growth ratescurr surprisescurr bristol-my squibb| celgene| januari
stock price show downward trend quarter averag share trade
quarter
volatil well period declin period
stock price show huge fluctuat year dip januari
announc celgen acquisit
rang stock stock price declin past one year
stock price show huge fluctuat past declin past stock
trade around juli huge dip octob went
couldnt surg back till date
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
